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INTRODUCTION
============

Circular RNAs (circRNAs) are a class of closed circular RNA molecules that rarely encode proteins and have no 5 'caps and 3' poly(A) tails. Their unique characteristics, such as better stability and resistance to nucleases make circRNAs potential candidates for clinical diagnostic/prognostic biomarkers \[[@r1]\]. The molecular mechanisms of circRNAs are diverse. In addition to acting as miRNA sponges, they may also play a role by binding protein or DNA sequences \[[@r2]--[@r4]\]. Some of them can also regulate gene expression by affecting RNA splicing or translating into short peptides \[[@r5]\]. They are conserved among different species, and also exhibit tissue-specific and developmental-stage specific traits \[[@r6]\]. Emerging evidences suggest that circRNAs are likely to play important function in different physiological or pathological processes. A multitude of studies have demonstrated that circRNAs are associated with various diseases, including cancer, Alzheimer's disease, ovarian endometriosis, preeclampsia \[[@r7]--[@r11]\]. Moreover, a previous study has reported that there are 15,996 circRNAs in normal human testis and more than 20 testis-derived circRNAs are stably expressed in seminal plasma \[[@r5]\]. All the above evidences indicate that circRNAs might play a role in spermatogenesis and maturation. However, the global expression and function of circRNAs in non-obstructive azoospermia (NOA) are largely unknown.

NOA is considered a major cause of male infertility \[[@r12], [@r13]\], which can't be completely cured by assisted reproductive technology (ART). Several genetic and epigenetic factors, especially Y chromosome microdeletion, are associated with the pathogenesis NOA \[[@r14]--[@r18]\]. In recent years, genome-wide association analysis (GWAS), has led to the identification of a few key NOA risk loci including PRMT6, PEX10, HLA-DRA \[[@r14], [@r16]\]. In addition to these genetic factors, epigenetic factors also play an important role in the development of NOA. For instance, Chencheng Yao et al. found that there were many differentially expressed miRNAs in testicular spermatogonia, pachytene spermatocytes, and round spermatids between NOA and OA patients \[[@r13]\]. Further, another group also found that miRNA-188-3p could regulate spermatogenic cell apoptosis by targeting MLH1 \[[@r19]\]. However, the epigenetic regulatory mechanisms, especially the role of circRNAs, in NOA are yet unknown.

Hence, the purpose of this study was to elucidate the expression profile of circRNAs and unravel the possible functions and interactions of circRNAs in NOA.

RESULTS
=======

Identification of the dysregulated circRNAs between NOA and OA groups
---------------------------------------------------------------------

We performed microarray-based profiling analyses to screen the differentially expressed circRNAs in 6 NOA and 3 OA tissues. The box plot depicts similar distributions of the intensities from all the normalized datasets ([Figure 1A](#f1){ref-type="fig"}). Raw variation of circRNA expression between the two groups is shown in the scatter plot ([Figure 1B](#f1){ref-type="fig"}). Volcano plots and hierarchical clustering exhibit the differentially expressed circRNAs between the NOA and OA samples ([Figure 2A](#f2){ref-type="fig"} and [2B](#f2){ref-type="fig"}). Using a threshold of fold change (FC) ≥ 1.5 and a p-value \< 0.05, we identified 82 differentially expressed circRNAs, of which 16 were up-regulated and 66 were down-regulated in NOA tissues compared with OA tissues ([Table 1](#t1){ref-type="table"} and [Table 2](#t2){ref-type="table"}). According to the annotation of human circRNAs, we found 81.71% of the dysregulated circRNAs were exonic circRNAs, 9.76% were intronic circRNAs and 8.54% were sense overlapping circRNAs ([Figure 2C](#f2){ref-type="fig"}). Further analysis revealed that these dysregulated circRNAs were mostly distributed on chr1, chr2, chr3, chr4, chr5, chr6, chr7, chr8, chr9, chr10, chr11, chr12, chr13, chr14, chr16, chr17, chr19, chr20, chr21 and chr22, but not on chr15, chr18, chrX and chrY ([Figure 2D](#f2){ref-type="fig"}).

![**Box plot and scatter plot of circRNA signal value variation in OA and NOA samples.** (**A**) The distribution of circRNAs for the nine samples. (OA: obstructive azoospermia; NOA: non-obstructive azoospermia). (**B**) Scatter plot showed variations in circRNA expression between OA and NOA samples. CircRNAs located above the top green line and below the bottom green line were more than 1.5-fold between OA and NOA samples.](aging-12-102765-g001){#f1}

###### Significantly upregulated circRNAs in NOA.

  ---------------------------------------- ------------- ------------- -------------- ---------------- --------------------
  **Significantly upregulated circRNAs**                                                               
  **probeID**                              **P-value**   **FDR**       **FC (abs)**   **Regulation**   **circRNA**
  ASCRP3001555                             0.0461916     0.957391589   1.52275        up               hsa_circRNA_401590
  ASCRP3002427                             0.016655094   0.957391589   1.5038532      up               hsa_circRNA_002032
  ASCRP3002765                             0.035853368   0.957391589   2.2698958      up               hsa_circRNA_072697
  ASCRP3003870                             0.010571567   0.957391589   1.7599646      up               hsa_circRNA_101130
  ASCRP3004000                             0.03573483    0.957391589   1.5243845      up               hsa_circRNA_100452
  ASCRP3006656                             0.019589109   0.957391589   1.7348182      up               hsa_circRNA_103916
  ASCRP3007758                             0.028997996   0.957391589   1.5351706      up               hsa_circRNA_070294
  ASCRP3007963                             0.019122487   0.957391589   1.7931198      up               hsa_circRNA_001512
  ASCRP3009230                             0.027775787   0.957391589   1.5701942      up               hsa_circRNA_031757
  ASCRP3009252                             0.004415576   0.957391589   1.5314721      up               hsa_circRNA_104078
  ASCRP3009351                             0.01558938    0.957391589   1.5958358      up               hsa_circRNA_073942
  ASCRP3010355                             0.013282587   0.957391589   1.6874562      up               hsa_circRNA_030050
  ASCRP3010888                             0.036692735   0.957391589   1.6901888      up               hsa_circRNA_103075
  ASCRP3011370                             0.042166787   0.957391589   1.5615877      up               hsa_circRNA_406996
  ASCRP3011901                             0.042668697   0.957391589   2.3337021      up               hsa_circRNA_001506
  ASCRP3012974                             0.037931142   0.957391589   1.5484401      up               hsa_circRNA_002006
  ---------------------------------------- ------------- ------------- -------------- ---------------- --------------------

###### Significantly downregulated circRNAs in NOA

  ------------------------------------------ ------------- ------------- -------------- ---------------- --------------------
  **Significantly downregulated circRNAs**                                                               
  **probeID**                                **P-value**   **FDR**       **FC (abs)**   **Regulation**   **circRNA**
  ASCRP3000334                               0.016382909   0.957391589   1.7917313      down             hsa_circRNA_403874
  ASCRP3000537                               0.004831071   0.957391589   1.6995075      down             hsa_circRNA_001937
  ASCRP3000663                               0.021040239   0.957391589   1.6627497      down             hsa_circRNA_406402
  ASCRP3000825                               0.002705609   0.957391589   1.5361052      down             hsa_circRNA_406267
  ASCRP3000954                               0.005248263   0.957391589   1.746061       down             hsa_circRNA_402130
  ASCRP3000991                               0.037238178   0.957391589   1.730753       down             hsa_circRNA_406822
  ASCRP3001155                               0.045260941   0.957391589   1.536961       down             hsa_circRNA_029998
  ASCRP3001768                               0.025224767   0.957391589   2.7399933      down             hsa_circRNA_406168
  ASCRP3001923                               0.048642805   0.957391589   3.3645337      down             hsa_circRNA_025349
  ASCRP3002888                               0.049366594   0.957391589   1.6916213      down             hsa_circRNA_402150
  ASCRP3002953                               0.012038305   0.957391589   1.6022409      down             hsa_circRNA_406503
  ASCRP3003279                               0.036135037   0.957391589   1.9818485      down             hsa_circRNA_406775
  ASCRP3003518                               0.035892518   0.957391589   2.4505456      down             hsa_circRNA_101053
  ASCRP3003843                               0.018020351   0.957391589   1.9115564      down             hsa_circRNA_406194
  ASCRP3003942                               0.00052197    0.957391589   1.5953273      down             hsa_circRNA_406419
  ASCRP3003975                               0.009862311   0.957391589   1.5153189      down             hsa_circRNA_103161
  ASCRP3004118                               0.036664644   0.957391589   1.5911543      down             hsa_circRNA_103141
  ASCRP3004393                               0.026087538   0.957391589   1.5282233      down             hsa_circRNA_067007
  ASCRP3004478                               0.010656101   0.957391589   1.5616605      down             hsa_circRNA_102558
  ASCRP3004662                               0.033021538   0.957391589   1.7230277      down             hsa_circRNA_000780
  ASCRP3004702                               0.022526843   0.957391589   1.5259744      down             hsa_circRNA_015279
  ASCRP3004757                               0.012437973   0.957391589   2.2150382      down             hsa_circRNA_104935
  ASCRP3005255                               0.047336724   0.957391589   1.5978168      down             hsa_circRNA_007328
  ASCRP3005451                               0.001349981   0.957391589   1.5599409      down             hsa_circRNA_103867
  ASCRP3005694                               0.04141577    0.957391589   1.6261871      down             hsa_circRNA_101894
  ASCRP3005793                               0.031346564   0.957391589   1.6079474      down             hsa_circRNA_102966
  ASCRP3006067                               0.009529304   0.957391589   1.5492371      down             hsa_circRNA_103348
  ASCRP3006096                               0.038650961   0.957391589   1.5329346      down             hsa_circRNA_023576
  ASCRP3006334                               0.010459305   0.957391589   1.5086231      down             hsa_circRNA_400185
  ASCRP3006335                               0.023372267   0.957391589   2.2086086      down             hsa_circRNA_404655
  ASCRP3006336                               0.046143308   0.957391589   1.8350186      down             hsa_circRNA_104940
  ASCRP3006936                               0.025160274   0.957391589   1.9992925      down             hsa_circRNA_102166
  ASCRP3007419                               0.025860647   0.957391589   1.5221658      down             hsa_circRNA_006604
  ASCRP3007490                               4.4193E-05    0.587369562   1.5977581      down             hsa_circRNA_406768
  ASCRP3007702                               0.047580725   0.957391589   1.5580697      down             hsa_circRNA_000883
  ASCRP3007956                               0.034250275   0.957391589   2.0042991      down             hsa_circRNA_006710
  ASCRP3008513                               0.032785099   0.957391589   2.0605802      down             hsa_circRNA_403457
  ASCRP3008758                               0.022383408   0.957391589   2.1321055      down             hsa_circRNA_400696
  ASCRP3008931                               0.035547528   0.957391589   1.7530169      down             hsa_circRNA_001695
  ASCRP3009069                               0.014371347   0.957391589   1.5358115      down             hsa_circRNA_103601
  ASCRP3009323                               0.046773984   0.957391589   1.6990883      down             hsa_circRNA_100166
  ASCRP3009406                               0.027542185   0.957391589   2.1979834      down             hsa_circRNA_102232
  ASCRP3009440                               0.031767553   0.957391589   1.7600919      down             hsa_circRNA_007624
  ASCRP3009894                               0.021930582   0.957391589   1.6907468      down             hsa_circRNA_002141
  ASCRP3009982                               0.009261095   0.957391589   2.1517926      down             hsa_circRNA_002796
  ASCRP3010075                               0.006608806   0.957391589   1.7673139      down             hsa_circRNA_051123
  ASCRP3010266                               0.042141617   0.957391589   1.6013384      down             hsa_circRNA_103181
  ASCRP3010752                               0.049588744   0.957391589   1.531321       down             hsa_circRNA_405511
  ASCRP3011101                               0.031160151   0.957391589   1.9640111      down             hsa_circRNA_059085
  ASCRP3011253                               0.020745727   0.957391589   1.6280942      down             hsa_circRNA_003145
  ASCRP3011607                               0.027895917   0.957391589   1.6782159      down             hsa_circRNA_092478
  ASCRP3011736                               0.039612091   0.957391589   1.7179174      down             hsa_circRNA_407124
  ASCRP3011751                               0.023198686   0.957391589   1.6108817      down             hsa_circRNA_100812
  ASCRP3011979                               0.048109527   0.957391589   1.5443097      down             hsa_circRNA_008142
  ASCRP3012222                               0.047250017   0.957391589   1.6431699      down             hsa_circRNA_001752
  ASCRP3012384                               0.032114065   0.957391589   1.9400004      down             hsa_circRNA_403560
  ASCRP3013001                               0.021611589   0.957391589   2.4807294      down             hsa_circRNA_003671
  ASCRP3013007                               0.002843475   0.957391589   1.5463175      down             hsa_circRNA_102552
  ASCRP3013008                               0.001979569   0.957391589   1.6561938      down             hsa_circRNA_102551
  ASCRP3013058                               0.033675352   0.957391589   1.6553273      down             hsa_circRNA_406350
  ASCRP3013126                               0.043940509   0.957391589   2.3814219      down             hsa_circRNA_402731
  ASCRP3013133                               0.035888866   0.957391589   1.5808639      down             hsa_circRNA_000328
  ASCRP3013332                               0.004952971   0.957391589   1.5817435      down             hsa_circRNA_104168
  ASCRP3013372                               0.042368459   0.957391589   1.8241931      down             hsa_circRNA_068259
  ASCRP3013501                               0.029805804   0.957391589   1.6140515      down             hsa_circRNA_100900
  ASCRP3013569                               0.038372041   0.957391589   2.7556443      down             hsa_circRNA_100981
  ------------------------------------------ ------------- ------------- -------------- ---------------- --------------------

![**Characterization of differentially expressed circRNA in OA and NOA samples.** (**A**) The volcano plots display the differential circRNAs expression between the two groups. Red points denote the differentially expressed circRNAs with statistical significance. (fold change ≥1.5 and p \<0.05). (**B**) Heatmap shows the 16 up-regulated circRNAs and 66 down-regulated circRNAs in NOA. (**C**) The pie charts show the origin of transcription of differentially expressed circRNAs. (**D**) The chromosomal location of differentially expressed circRNAs is shown in the last figure. Red: up-regulated circRNAs in NOA; green: down-regulated circRNAs in NOA.](aging-12-102765-g002){#f2}

Validation of circRNAs using qRT-PCR
------------------------------------

To further confirm the results of circRNA microarray, we chose six dysregulated circRNAs at random, including three down-regulated (hsa_circRNA_402130, hsa_circRNA_100812 and hsa_circRNA_406168) and three up-regulated (hsa_circRNA_072697, hsa_circ RNA_104078 and hsa_circRNA_030050). qRT-PCR in NOA and OA samples showed that the expression of hsa_circRNA_072697, hsa_circRNA_402130, hsa\_ circRNA_100812, hsa_circRNA_030050 and hsa_circ RNA_406168 was consistent with the microarray data. And the difference in expression of hsa_circ RNA_072697, hsa_circRNA_030050, hsa_circRNA\_ 100812, hsa_circRNA_402130 and hsa_circRNA_406168 was statistically significant ([Figure 3A](#f3){ref-type="fig"}, [3C](#f3){ref-type="fig"}, [3D](#f3){ref-type="fig"}, [3E](#f3){ref-type="fig"}, [3F](#f3){ref-type="fig"}, p=0.0332, p=0.0156, p=0.0482, p=0.0139, p=0.0164). The expression of hsa_circRNA_104078, however, did not follow the microarray and was not statistically significant ([Figure 3B](#f3){ref-type="fig"}, p=0.2795).

![**Confirmation of the six candidate circRNAs by qRT-PCR.** All RNAs of 6 NOA and 3 OA patients were included**.** The experiments were repeated three times. 2-ΔΔCt method was used to measure gene expression. The values are presented as the mean ± SE.](aging-12-102765-g003){#f3}

MicroRNA response elements analysis of validated circRNAs
---------------------------------------------------------

Several studies have demonstrated that circRNAs regulate the expression of their target genes by competing with their target miRNAs for binding \[[@r8], [@r20], [@r21]\]. The Arraystar's homemade miRNA target prediction software based on TargetScan and miRanda was utilized to predict the circRNA-microRNA interactions of two confirmed circRNAs (hsa_circRNA_402130 and hsa_circRNA\_ 072697). The top 5 targeted miRNAs were then identified based on the miRNA support vector regression (mirSVR) scores. Studies have shown that some NOA-related miRNAs are dysregulated in the testicular tissues of patients with NOA \[[@r22], [@r23]\]. So we selected the the potential miRNAs shared by the software and the reports to construct circRNA--miRNA interactions. The 2D structure was created from the sequence analysis of microRNA response elements (MREs) ([Figure 4A](#f4){ref-type="fig"} and [4B](#f4){ref-type="fig"}). For hsa_circRNA_402130, the potential miRNA targets included hsa-let-7b-5p, hsa-let-7c-5p and hsa-let-7i-5p, and for hsa_circRNA_072697 the miRNA included hsa-miR-23c and hsa-miR-182-5p.

![**Prediction of circRNA/miRNA interactions by Arraystar's homemade miRNA target prediction software based on TargetScan and miRanda.** (**A**) The potential miRNA targets of hsa_circRNA_402130. (**B**) The potential miRNA targets of hsa_circRNA_072697. Local AU: Schematic diagram of the AU weights on both sides of the seed site. The empty square under "Conservation" indicates the lack of conserved information of circRNA between the species. M: miRanda; T: TargetScan.](aging-12-102765-g004){#f4}

CircRNA-miRNA-mRNA interaction analysis
---------------------------------------

To dissect out the functions of the two validated circRNAs, starBase v2.0 and miRDB identified down-stream target genes of the abovementioned candidate miRNAs. The two circRNA-miRNA-mRNA regulatory networks (built by OmicShare tools) included 3 miRNAs and 212 mRNAs in the ceRNA network of hsa_circRNA_402130 ([Figure 5A](#f5){ref-type="fig"}, [Supplementary Table 1](#SD2){ref-type="supplementary-material"}), and 2 miRNAs and 411 mRNAs in the ceRNA network of hsa_circRNA_072697 ([Figure 5B](#f5){ref-type="fig"}, [Supplementary Table 2](#SD3){ref-type="supplementary-material"}). As shown in [Figure 5A](#f5){ref-type="fig"}, we found that this network contains multiple transcription factors such as HMGA2, SOX13, E2F5, LIN28B and so on. Similarly, multiple transcription factors such as FOXO3, FOXP2 and SP3 are included in the regulatory network of [Figure 5B](#f5){ref-type="fig"}. These regulatory networks revealed that circRNAs may play a crucial part in the process of NOA.

![**CircRNA-miRNA-mRNA network analysis.** (**A**) The ceRNA network of hsa_circRNA_402130. The network consists of 3 miRNAs and 212 genes with 631 relationships. (**B**) The ceRNA network of hsa_circRNA_072697. The network consists of 2 miRNAs and 411 genes with 425 relationships. The yellow round node represents a protein-coding gene, blue triangle node represents a miRNA and a green hexagon represents a circRNA.](aging-12-102765-g005){#f5}

GO and KEGG enrichment analysis of the predicted network genes for hsa_circRNA_402130 and hsa_circRNA_072697
------------------------------------------------------------------------------------------------------------

The functions of all the target genes were analyzed by online biological classification tool DAVID. The top 10 GO terms and KEGG terms are displayed as bubble diagram. The GO biological process (BP) analysis ([Figure 6A](#f6){ref-type="fig"}) showed that the target genes were significantly enriched in positive regulations including transcription from RNA polymerase II promoter, transcription, cell migration, protein phosphorylation, palate development, pathway-restricted SMAD protein phosphorylation, circadian regulation of gene expression. KEGG pathway analysis ([Figure 6B](#f6){ref-type="fig"}), showed target genes were enriched for microRNAs in cancer, MAPK signaling pathway, signaling pathways regulating pluripotency of stem cells, FoxO signaling pathway, ubiquitin mediated proteolysis, axon guidance, transcriptional misregulation in cancer, proteoglycans in cancer and TNF signaling pathway. These findings imply that circRNAs might participate in the development of NOA through multiple signaling pathways.

![**GO and KEGG enrichment analysis of hsa_circRNA_402130 and hsa_circRNA_072697.** (**A**) Gene ontology (GO) enrichment analysis of the two circRNAs predicted target genes in terms of biological processes (BP). (**B**) KEGG enrichment analysis of the two circRNAs predicted target genes. The top 10 significantly enriched activities were shown above. The size of each circle indicates the counting number on each part, while the color represents the negative logarithm of p value of the enrichment analysis.](aging-12-102765-g006){#f6}

DISCUSSION
==========

Results from the Human Genome Project and the DNA Elements Encyclopedia Project indicated that protein-coding gene sequences account for only 1-3% of the human genome sequence. Also, most of the transcribed sequences in the human genome are non-coding RNA sequences \[[@r24]\]. Studies demonstrated that non-coding RNAs including miRNAs and lncRNAs participate in the occurrence and development of NOA \[[@r13], [@r18], [@r22], [@r23], [@r25]--[@r27]\]. However, the role of circRNAs, a class of non-coding RNA, has not been reported in NOA.

Here, we constructed the expression profile of circRNAs in NOA by high-throughput circRNA microarray for the first time. 16 up-regulated and 66 down-regulated circRNAs in NOA were identified. As most of these circRNAs originate from exons or introns, these results imply that dysregulated expression of circRNAs may be involved in the process of NOA. Subsequently, differential expression of circRNAs was confirmed by qRT-PCR. As circRNAs usually function as RNA sponge to regulate gene expression \[[@r4], [@r20], [@r21]\], bioinformatics was used to predict target miRNAs of hsa_circRNA_402130 and hsa_circRNA_072697. The results showed that hsa-let-7b-5p, hsa-let-7c-5p and hsa-let-7i-5p had a binding site for hsa_circRNA_402130, and hsa-miR-23c and hsa-miR-182-5p had a binding site for hsa_circRNA\_ 072697. These indicated that hsa-let-7c-5p, hsa-let-7b-5p and hsa-let-7i-5p were the targets for hsa\_ circRNA_402130, and hsa-miR-23c and hsa-miR-182-5p were the targets for hsa_circRNA_072697. In addition, these predicted miRNAs were previously reported that hsa-let-7b-5p, hsa-let-7c-5p and hsa-let-7i-5p were up-regulated and hsa-miR-23c and hsa-miR-182-5p were down-regulated in NOA \[[@r22], [@r23]\]. Among these target miRNAs, let-7 family is an important regulator of stemness by regulating LIN28A, a gene that plays pivotal roles in organogenesis, embryonic development and tumorigenesis \[[@r28]--[@r30]\]. Jixin Tang et al. \[[@r31]\] indicated that let-7 miRNA family (let-7c-5p and let-7i-5p) regulate spermatogenesis in mice through LIN28A. Another member of the let-7 miRNA family let-7g could significantly reduce the germ cell pool in mice \[[@r32]\]. Based on these findings, we speculate that hsa_circRNA_402130 may cause NOA by regulating the expression of let-7 miRNA family.

Moreover, based on the above two circRNAs, we constructed "circRNA-miRNA-mRNA" ceRNA regulatory networks. From these regulatory networks, we found many transcription factors that regulate spermatogenesis. Studies have shown that SP3 presents a unique expression pattern during spermatogenesis in mice and other mammalian \[[@r33], [@r34]\]. It has been confirmed that HMGA2 was expressed during the process from spermatocyte to spermatid in mice, and the phenotype of HMGA2-null mice was few spermatids and complete absence of spermatozoa \[[@r35]\]. We also found some protein coding genes that are affected by let-7 miRNAs involved in spermatogenesis. TET3 is expressed in round spermatids and sperm and its effect on sperm methylome might be essential in human \[[@r36]\]. As early as 2006, a group found that CDC25A was down-regulated in the testis tissue of male infertile patients \[[@r37]\]. Subsequent studies suggested that CDC25A might be regulated by BOLL and participate in human spermatogenesis \[[@r38]\]. These evidences all indirectly indicated that circRNAs were involved in spermatogenesis. However, experiments are required to confirm these interactions and, to elucidate the localization of circRNAs and target miRNAs.

Additionally, we also performed GO and KEGG enrichment analysis of miRNA target genes for the first time. GO enrichment analysis revealed miRNA target genes that positively regulate transcription from RNA polymerase II promoter, transcription, cell migration, protein phosphorylation, palate development, pathway-restricted SMAD protein phosphorylation, circadian regulation of gene expression and so on. Given that phosphorylation of SMAD promotes differentiation of mouse SSC \[[@r39]\], and proliferation of germ cells in mice \[[@r40]\], it is possible that circRNAs may regulate spermatogenesis by affecting SMAD activity in NOA patients. Among the KEGG pathways associated with the two circRNAs, FoxO signaling pathway and MAPK signaling pathway are strongly associated with spermatogenesis in mice \[[@r41]--[@r43]\]. Based on our and previous data, we can easily say that humans and mice share many common ways in the regulation of spermatogenesis. More studies on NOA patients should be conducted to improve our understanding of the mechanisms of spermatogenesis and NOA to validate the results of animal experiments. In addition, we identified a signaling pathway involved in regulation pluripotency of stem cells within the network of the dysregulated circRNAs. This is significant as self-renewal and mitosis of spermatogonial stem cells are important steps in human spermatogenesis. Based on the abovementioned ceRNA networks and enrichment analysis results, we have discovered many molecules and pathways related to stemness. Thus, we suspect that these two circRNAs may be involved in the development of NOA by regulating the stemness of spermatogonial stem cells. In a word, our study provides new ideas and strategies for NOA research. But whether circRNAs are involved in these processes deserves to be confirmed by subsequent *in vitro* and *in vivo* experiments.

Our study also has two limitations. First, more testicular tissue samples could be included in this study. This might reduce the error caused by individual differences of patients. In addition, due to the difficulties in acquiring testicular samples, we were unable to use the testicular samples of volunteers who had already been known fertility and normal spermatogenesis as normal controls.

In summary, this is the first report that reveals the expression profile of differentially expressed circRNAs and, in conjunction with bioinformatics analysis, provides the first assessment of ceRNA networks and circRNAs associated pathways in NOA. Results indicated that circRNAs may play important functions and have potential to become therapeutic targets for NOA.

MATERIALS AND METHODS
=====================

Testicular tissue samples collection
------------------------------------

The study was approved by the Ethics Committee of the Institute of Human Reproduction and Stem Cell Engineering of Central South University. Testicular biopsies were collected from 6 NOA and 3 OA patients. All participants signed informed consent, and routine semen analysis based on the World Health Organization criteria showed no sperm. Most patients have been tested for follicle-stimulating hormone (FSH), luteinizing hormone (LH) and testosterone (T). All the patients underwent testicular fine needle aspiration for histological examination at Reproductive and Genetic Hospital of CITIC-Xiangya. Those patients without testicular sperm were defined as NOA patients. OA patients had normal spermatogenic function accompanied by blockage of the vas deferens, but no other congenital diseases. The results of the pathological examinations are in the ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). None of the patients were exposed to radiation, high temperature or toxic substances prior to their hospitalization. NOA patients with chromosomal abnormalities, Y chromosome microdeletion, and varicocele were excluded from the study.

Total RNA extraction
--------------------

Nine RNA samples of testicular biopsies from NOA and OA patients were extracted using TRIzol (Invitrogen, USA) following the manufacturer's protocol. The quantity and purity of total RNA was measured on the NanoDrop® ND-1000 spectrophotometer (Thermo Fisher, USA). RNA integrity was measured by denaturing agarose gel electrophoresis.

Microarray detection
--------------------

All RNA samples were analyzed by Arraystar circRNA Microarray at Kangchen Bio-tech (Shanghai, China). Sample labeling and array hybridization were performed according to the manufacturer's protocol (Arraystar Inc.). The hybridized arrays were washed, fixed and scanned on the Agilent Scanner G2505C. Agilent Feature Extraction software was used for raw data extraction. The data was then processed using the limma package of R software. Low intensity was filtered after quantile normalization of the raw data. Student's t-test was used to estimate the statistical significance between groups. CircRNAs with a fold change ≥ 1.5 and p \< 0.05 were considered significant.

Quantitative real-time reverse transcription PCR
------------------------------------------------

The cDNA was prepared from 1ug of total RNA using Super Script TMIII Reverse Transcriptase kit (Invitrogen) according to the manufacturer's instructions. Quantitative real-time reverse transcription PCR (qRT-PCR) was performed using a 2×PCR master mix (Arraystar) on the ViiA 7 Real-time PCR System (Applied Biosystems) to detect the relative expression levels of target circRNAs. The primer sequences for the target circRNAs are as follows: hsa\_ circRNA_402130 forward: 5′-GTGGCCGAGGACTTTGATTG-3′, reverse: 5′-CCTGTAACAACGCATCTCATATT-3′; hsa_circRNA_100812 forward: 5′-TATTCTCAAGCTGTCACAGGACATT-3′, reverse: 5′-TGAGGGTAGCAGCAGAACGAG-3′; hsa_circRNA_072697 forward: 5′-TGATAGAAAAGTTAGAATTTTCAGA-3′, reverse: 5′-ACTCTTTCAAACTCTAAGAGCTTAG-3′; hsa_circRNA_104078 forward: 5′-GCTTATGGCTATAAAATTACAGAGA-3′, reverse: 5′-CGGGACAACATCCTTTCTTAC-3′; hsa_circRNA_030050 forward: 5′-GGGAGAAGCAGCTAGAACCA-3′; reverse: 5′-TT TGCCAGAATACCCCTTTG-3′; hsa_circRNA_406168 forward: 5′-ATTGGGTTCTTTGCCTGTTG-3′; reverse: 5′-GGGGCAGACAGATGAGAAAG-3′; β-actin forward: 5′-GTGGCCGAGGACTTTGATTG-3′, reverse: 5′-CCTGTAACAACGCATCTCATATT-3′. Transcript level of the housekeeping gene β-actin was used to normalize the relative expression of circRNAs. Data is represented as mean ± SE of three independent experiments.

Annotation and functional prediction of hsa_circRNA_402130 and hsa_circRNA_072697
---------------------------------------------------------------------------------

The circRNA-microRNA interactions of hsa_circRNA_402130 and hsa_circRNA_072697 were predicted with Arraystar's home-made microRNA target prediction software based on TargetScan \[[@r44]\] and miRanda \[[@r45]\]. The analysis process of the software is as follows: First, it performs target prediction by using the miRNA information in the latest miRBase on the target sequence. Then, candidate miRNAs are screened by Context+\<=-0.05 and Context\<=-0.05. Finally, according to the miRNA coverage of MREs (MicroRNA Recoginition Elements) on the target sequence, the required circRNA-microRNA interactions are obtained. The microRNA-mRNA interactions were predicted by starBase v2.0 (<http://starbase.sysu.edu.cn/browser.php>) \[[@r46], [@r47]\] and miRDB (<http://www.mirdb.org>) \[[@r48], [@r49]\]. GO and KEGG enrichment analysis of circRNA-targeting genes were performed by DAVID <https://david.ncifcrf.gov/>. Then OmicShare tools (<http://www.omicshare.com/tools>) was used to create potential maps of the circRNA/miRNA/mRNA interaction networks of hsa_circ_402130 and hsa_circ_072697.

Statistical analysis
--------------------

Student's t-test (two-tailed) was used to estimate statistical significance between groups. Data analysis was performed using GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA). A p-value \< 0.05 was considered significant.
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